What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

Should We Abandon Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer? A Meta-Analysis

“…Of the included studies only two, Omali et al [26] and Yuanming et al [28], reported no benefit with the use of intraperitoneal chemotherapy. Omali et al included patients in the GOG 104, 114, and 172 studies, and they report on long-term survivors (>10 years of survival).…”

“…The use of intraperitoneal chemotherapy was not found to be an independent survival factor. They also included patients who were treated with cyclophosphamide in the intravenous arm, although this that is not first line in the treatment of ovarian cancer [26]. Similarly, Yuanming et al used a lower dose in the IP group than that used in previous studies, and it is possible that the expected benefits of this treatment were not evident as the theoretical positive effect of this route of administration is based on the cumulative effect and dose in peritoneal cavity assuming an increase in side effects.…”

“…GOG 172 reported the greatest increase in overall survival in these patients, which increased by 16 months [12,13,17,33,34]. However, intraperitoneal chemotherapy is still rarely used as the first-line treatment in clinical practice due to the high toxicity; incon-venience; risk of catheter-related complications; and lack of a widely accepted optimal regimen [26,27].…”